LPCAT2 controls chemoresistance in colorectal cancer

Lipid droplets (LD) are now-well recognized as playing a role in cancer progression, however their potential role in chemoresistance remains largely unknown, particularly in colorectal cancer (CRC). We recently highlighted that LD accumulate in CRC cells under the control of lysophosphatidylcholine...

Full description

Saved in:
Bibliographic Details
Published inMolecular & cellular oncology Vol. 5; no. 3; p. e1448245
Main Authors Cotte, Alexia Karen, Aires, Virginie, Ghiringhelli, François, Delmas, Dominique
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2018
Taylor et Francis
Taylor & Francis Group
Subjects
Author's Views
Cancer
chemoresistance
colorectal cancer
immunogenic cell death
Life Sciences
Lipid droplets
LPCAT2
chemoresistance
colorectal cancer
Lipid droplets
LPCAT2
immunogenic cell death
Online AccessGet full text

Cover

More Information
Summary:Lipid droplets (LD) are now-well recognized as playing a role in cancer progression, however their potential role in chemoresistance remains largely unknown, particularly in colorectal cancer (CRC). We recently highlighted that LD accumulate in CRC cells under the control of lysophosphatidylcholine acyltransferase 2 (LPCAT2) enzyme expression. We also showed that chemotherapy-induced LD accumulation counteracts intrinsic and extrinsic cancer cell death activation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC6149788
Pr. Dominique Delmas, INSERM UMR1231, UFR des Sciences de Santé, 7 Bd Jeanne d'Arc, 21000 Dijon, France (33) 3-80-39-32-26, dominique.delmas@u-bourgogne.fr
Dr. Virginie Aires, INSERM UMR1231, UFR des Sciences de Santé, 7 Bd Jeanne d'Arc, 21000 Dijon, France (33) 3-80-39-32-26, (33) 3-80-39-33-53, Virginie.Aires02@u-bourgogne.fr
Dr. Alexia Karen Cotte, INSERM UMR1231, UFR des Sciences de Santé, 7 Bd Jeanne d'Arc, 21000 Dijon, France (33) 3-80-39-33-53, Alexiakm.cotte@gmail.com
Pr. François Ghiringhelli, Département d'oncologie médicale, Centre Georges-François Leclerc – INSERM U866, 1, Rue du Professeur Marion, 21079 Dijon Cedex, France (33) 3-80-73-75-00, francois.ghiringhelli@yahoo.fr
ISSN:2372-3556
2372-3556
DOI:10.1080/23723556.2018.1448245